2026/0159 - Invitation to submit proposals under framework agreement(s) 961/2024 - Various Medicines, 2025/1627 - Cardiovascular System Medicines, 900/2024 - Antiretroviral Medicines for HIV Infection Treatment, 899/2024 - Respiratory System Medicines, 780/2024 – Musculoskeletal System Medicines, used in the treatment of endocrine diseases and hormones, 491/2023 - Oncological Medicines and Immunomodulators, 492/2023 - Anti-infective Medicines

This tender, identified as 2026/0159, is an invitation for proposals related to several existing framework agreements for the supply of various categories of medicines. These include general 'Various Medicines' (under framework 961/2024), medications for the cardiovascular system (framework 2025/1627), antiretrovirals for HIV treatment (framework 900/2024), respiratory system medications (framework 899/2024), musculoskeletal system medications for endocrine and hormonal diseases (framework 780/2024), oncological and immunomodulatory drugs (framework 491/2023), and anti-infective agents (framework 492/2023). The procurement aims to secure a supply of these essential medicines through established agreements. Bidders who are parties to these framework agreements are invited to submit proposals according to the terms and conditions specified for each category. The objective is to ensure the continuous availability of a wide range of pharmaceuticals.

This is a supplies contract in the health and medical services and general supplies sectors. Located in Portugal, Europe, this opportunity is open to firms and consortiums, with an estimated budget of EUR 810.

Published through base_gov_pt, a national government procurement portal. Public procurement tenders follow the country's national bidding regulations and may have specific eligibility and documentation requirements for the supply of goods in the health and medical services sector. Supply contracts typically require bidders to demonstrate product compliance with technical specifications, delivery capacity, and relevant certifications. This contract has already been awarded. The information is published for transparency and market intelligence purposes.